Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chugai Pharmaceutical CoTSE:4519 -2.15%96 FCF Yield % is 2.79 as of Jul. 14, 2026, which is 15% above its 10-year median of 2.43. GuruFocus rates TSE:4519 with a GF Score™ of 96/100 and a GF Value™ of 円7,735.19 (Fairly Valued). The stock has 1 warning sign investors should review. Among 1,006 Drug Manufacturers companies, Chugai Pharmaceutical Co ranks better than 63.72% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Chugai Pharmaceutical Co FCF Yield % Related Terms
Chugai Pharmaceutical Co FCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4519 vs LLY, JNJ, ABBV: FCF Yield % Comparison
For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chugai Pharmaceutical Co FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Chugai Pharmaceutical Co's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chugai Pharmaceutical Co (TSE:4519) has a FCF Yield % of 2.79 as of Jul. 14, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Chugai Pharmaceutical Co and its competitors. This is 15% above median its historical median of 2.43. Over the past decade, Chugai Pharmaceutical Co's FCF Yield % has ranged from 0.03 to 6.05. According to the industry distribution chart, Chugai Pharmaceutical Co ranks #365 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 36.3%.
Is Chugai Pharmaceutical Co's FCF Yield % too high?
Chugai Pharmaceutical Co's current FCF Yield % of 2.79 is 15% above median its 10-year median of 2.43. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 6.05. The Drug Manufacturers industry median FCF Yield % is 0.67. Chugai Pharmaceutical Co's value of 2.79 is 316.4% above this industry median. Based on the distribution chart, Chugai Pharmaceutical Co ranks #365 out of 1006 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Chugai Pharmaceutical Co has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chugai Pharmaceutical Co's FCF Yield % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Chugai Pharmaceutical Co ranks #365 out of 1006 companies for FCF Yield %. This puts Chugai Pharmaceutical Co in the upper half of its industry. The industry median FCF Yield % is 0.67. Chugai Pharmaceutical Co's value of 2.79 is 316.4% above this benchmark. Historically, Chugai Pharmaceutical Co's own FCF Yield % has ranged from 0.03 to 6.05 over the past decade. While the company's 10-year median is 2.43 vs. the industry median of 0.67, Chugai Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.67, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chugai Pharmaceutical Co's current FCF Yield % of 2.79 is 316.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Chugai Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chugai Pharmaceutical Co's current FCF Yield % is 2.79, which is 15% above median its own 10-year median of 2.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chugai Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co (TSE:4519) is currently considered Fairly Valued. The stock's GF Value™ is 円7,735.19, compared to a current price of 円7,230.00 — trading 6.5% below its estimated fair value. The current FCF Yield % is 2.79, which is 15% above median its 10-year median of 2.43 and 316.4% above the Drug Manufacturers industry median of 0.67. Chugai Pharmaceutical Co's overall GF Score™ is 96/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Chugai Pharmaceutical Co (TSE:4519), the current FCF Yield % is 2.79 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chugai Pharmaceutical Co (TSE:4519) Overvalued in 2026?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co stock appears to be undervalued.
The current stock price of 円7,230.00 is trading 6.5% below its estimated GF Value™ of 円7,735.19.
GuruFocus considers Chugai Pharmaceutical Co to be Fairly Valued.
Key valuation signals for TSE:4519:
FCF Yield %: 2.79 (15% above median its 10-year median of 2.43)
GF Value™: 円7,735.19 vs. price of 円7,230.00 (6.5% below fair value)
Industry Position: 316.4% above the Drug Manufacturers median (#365 of 1006)
No single metric tells the full story. See the TSE:4519 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra (hemophilia), Actemra (rheumatoid arthritis, covid), Foundayo (oral obesity pill), and Nemluvio (atopic dermatitis, prurigo nodularis).
96GF Score
Get the complete analysis for TSE:4519
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4519 has been successfully added to your 
